DNX 114 - DNX Biopharmaceuticals/XL protein GmbH
Alternative Names: DNX-114Latest Information Update: 28 Nov 2022
At a glance
- Originator DNX Biopharmaceuticals; XL-protein GmbH
- Class Antipsoriatics; Antirheumatics; Biobetters; Proteins; Skin disorder therapies
- Mechanism of Action Tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for research development in Ankylosing-spondylitis in Germany
- 28 Nov 2022 No recent reports of development identified for research development in Ankylosing-spondylitis in USA
- 28 Nov 2022 No recent reports of development identified for research development in Juvenile-rheumatoid-arthritis in Germany